1. In order to develop an improved differential sugar absorption test for simultaneously assessing intestinal permeability and lactose intolerance, methods were established for determining raffinose, lactose and L-arabinose in human urine. Using NAD(P)H-coupled enzymatic assays and fluorimetry, each sugar was measurable over a concentration range of approximately 3-300 ,umol/l in diluted urine specimens.
INTRODUCTION
During the past decade, the non-invasive assessment of intestinal permeability by the use of orally administered, passively absorbed probe substances has increasingly been applied to the detection and management of intestinal disease [ 1-91. Current procedures include differential sugar absorption [l-51, absorption of labelled chelates such as 51Cr-ethylenediaminetetra-acetate [6, 71 or absorption of polymers such as poly( ethylene glycol) [8, 91, and all depend on measuring the urinary recovery of the metabolically inert probe( s). However, most differential sugar absorption tests use hyperosmolar sugar loads which impose substantial osmotic stress on the intestine [ 101 and rely on technically demanding chromatographic [l-3, 51 or relatively non-specific chemical [4] analysis.
Similarly, ethylene glycol polymers may suffer from unreliable quantification [ll], and those of lower mol.
wt. display anomalous permeation due to their lipid solubility [ 12-14]. Although easily measured, Wr-ethylenediaminetetra-acetate requires a 24 h urine collection for adequate diagnostic accuracy [6, 151 and is absorbed to a significant extent via the large intestine [13, 141; more seriously, it appears to be excessively sensitive to small changes in permeability in normal intestine [15, 161 but less reliable in detecting coeliac disease than a sugar test
The aim of this study was to develop an improved differential sugar absorption test based on the use of an isoosmotic mixture of the monosaccharide L-arabinose, the disaccharide lactose and the trisaccharide raffinose, which could be measured fluorimetrically in urine by a specific enzymatic assay. As well as providing an index of intestinal permeability based on raffinose excretion, it was anticipated that the test could also be used to detect lactosuria due to lactose maldigestion in patients with lactase deficiency. A preliminary account of part of this work has been communicated to the Medical Research Society of Great Britain [ 181.
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MATERIALS AND METHODS
Biochemicals
L-( + )-Arabinose, D-( + )-raffinose pentahydrate, Bgalactosidase type X, B-fructosidase ('Invertase') type VII, hexokinase/glucose-6-phosphate dehydrogenase, phosphoglucose isomerase type I11 and glucose oxidase type V were obtained from Sigma Chemical Company Ltd, Poole, Dorset, U.K., B-galactose dehydrogenase S and catalase suspension were from Boehringer Corporation, Lewes, E. Sussex, U.K., and a-lactose monohydrate (Analar) was from BDH Chemicals, Poole, Dorset, U.K. The arabinose, raffinose and lactose used were all chromatographically homogeneous. All other chemicals were of analytical grade.
Subjects
A group of patients (56 male, 87 female; median age 42 years, range 16-8 1 years) with gastrointestinal symptoms and clearly defined diagnosis was selected for study. Sixty-two patients in whom no pathological process could be found were diagnosed as having irritable bowel syndrome (IBS). Patients with coeliac disease were classified as untreated (1 5 patients, either newly diagnosed or in relapse, not adhering to a gluten-free diet and with subtotal villous atrophy proven by intestinal biopsy), in partial remission (19 patients, maintaining a gluten-free diet but with some degree of persisting villous atrophy) or in complete remission (16 patients, maintaining a glutenfree diet and with a histologically normal biopsy). Sixteen patients had Crohn's disease, of whom ten were judged on radiological grounds to have upper-small-bowel disease, and five had only terminal ileal or colonic involvement. There were six patients with ulcerative colitis and nine cases of lactase deficiency (jejunal lactase activity < 1 units/g of tissue). Healthy volunteers (hospital laboratory and medical staff: 27 male, 13 female; median age 28.5 years, range 20-50 years) were used as a reference group and were taking no medication at the time of the study. This study was approved by the Ethical Committee of the Central Manchester Health Authority.
Test protocol
After an overnight fast, subjects emptied their bladder and ingested a solution of 2.0 g of L-arabinose, 20 g of lactose and 8.0 g of raffinose in 250 ml of water. Urine was collected for 5 h thereafter. Subjects consumed no food during the test, but water was allowed ad libitum after 2 h had elapsed. After recording the urine volume, a 25 ml sample was mixed with thiomersalate (25 pmol/l final concentration) as a preservative and stored at -20°C for analysis. A sample of the pre-test urine was tested for glucose with a test strip (Diabur-2000; Boehringer) .
Urine analysis
Before analysis, frozen urine specimens were thawed and clarified by centrifugation at 3000 rev./min for 10 min. Urine was then pretreated to remove endogenous fluorophores and other contaminants by passage through C18-silica solid-phase extraction columns (BondElut LRC; Jones Chromatography Ltd, Hengoed, MidGlamorgan, U.K.). Columns were prepared for use by activation with acetonitrile, followed by rinsing with twice-distilled water. A 10 ml aliquot of urine was passed through each column and the final 2-4 ml was collected for analysis. The pretreated urine was diluted 20-to 200-fold for L-arabinose determination, one-to eight-fold for lactose determination, and two-to ten-fold for raffinose determination, depending on the total urine volume. In preliminary experiments, urinary fluorophores were removed by treatment with AG501-X8 mixed ionexchange resin (Bio-Rad Laboratories Ltd, Watford, Herts, U.K.) in the acetate form, essentially as described by Schersten & Tibbling [ 191. If present, endogenous glucose was removed from the urine by treatment with glucose oxidase and catalase. Pretreated urine (0.2 ml) was mixed with 0.2 ml of 0.5 mol/l 4-morpholine-ethanesulphonic acid buffer, pH 7.0, containing glucose oxidase (500 units/ml) and catalase (2.0 mglml), and incubated at 37°C for 3 h under continuous gassing with 95% 0,/5'/0 CO,. After incubation, the mixture was boiled to inactivate the enzymes and the precipitated protein was removed by centrifugation at 11000 g for 5 min. Water lost by evaporation was monitored by weighing the incubation tubes and was replaced after boiling.
L-Arabinose was measured by reaction with galactose dehydrogenase. Pretreated urine (100 p l ) was incubated at 37°C for 30 min with 1.0 ml of 0.1 mol/l potassium phosphate buffer, pH 7.7, containing 0.25 units of galactose dehydrogenase and 0.67 mmol/l NAD. Lactose was measured as glucose released by hydrolysis with Bgalactosidase. Pretreated urine (50 p l ) was mixed with 50 pl of 0.1 mol/l potassium phosphate buffer, pH 7.7, containing 12.5 units of b-galactosidase and incubated at 37°C for 30 min. After boiling for 2 min to inactivate the galactosidase, 1.0 ml of hexokinase reagent was added and incubation was continued at 37°C for a further 30 min. Hexokinase reagent contained 1 unit of hexokinase/ ml, 0.5 unit of glucose-6-phosphate dehydrogenase/ml, 5 mmol/l adenosine 5'-triphosphate, 0.84 mmol/l NADP and 8.0 mmol/l MgSO, dissolved in 0.3 mol/l Tris-HC1 buffer, pH 7.6. Precipitated protein was removed after incubation by centrifugation at 3000 rev./min for 10 min. Raffinose was measured as fructose released by hydrolysis with /?-fructosidase. Pretreated urine (50 p l ) was incubated at 37°C for 30 min with 50 p1 of 0.4 mol/l sodium citrate buffer, pH 4.6, containing 12.5 units of /?-fructosidase. After boiling to inactivate the fructosidase, 1 .O ml of hexokinase reagent containing phosphoglucose isomerase (10 units/ml) was added and incubation was continued at 37°C for 30 min.
For each sugar, fluorescence was measured at 25°C at an excitation wavelength of 345 nm and an emission wavelength of 475 nm, using a Perkin-Elmer LS-3B fluorescence spectrophotometer fitted with a 20 p1 flow cell and coupled to a Gilson model 222 automatic sample changer. Assays were calibrated with sugar standards carried through the entire analysis.
Calculation of results
Samples of the sugar drink were analysed in parallel with urine samples and the urinary excretion of each sugar was expressed as a percentage of the oral dose. Excretion ratios for raffinose and lactose were calculated as the percentage urinary recovery of each relative to that of L-arabinose. The statistical signhcance of results was evaluated with a two-tailed Mann-Whitney U-test, since most of the data were not normally distributed.
RESULTS
Removal of urinary fluorophores
Preliminary experiments indicated that there was considerable background fluorescence originating from endogenous urinary components. Attempts to remove this with charcoal [20] were unsuccessful and treatment with ion-exchange resin proved to be only partially satisfactory in that, although urinary fluorescence was substantially reduced, probe recovery was incomplete and somewhat variable. However, solid-phase extraction using a C18-silica matrix removed 79% of endogenous urinary fluorescence while consistently yielding approximately 90% recovery of the probe sugars ( Table 1) .
Removal of endogenous glucose
Although glucosuria was detected in less than 1% of patients studied, the amount of urinary glucose present in such cases (up to 200 mmol/l) was sufficient to preclude the determination of both lactose and raffinose. A procedure for the removal of endogenous glucose from urine was therefore developed, based upon the coupled oxidation of glucose by glucose oxidase and catalase [21] . In order to reduce the amount of endogenous glucose by the requisite four orders of magnitude within a reasonable time period, it was essential to use relatively large amounts of the two enzymes, to continuously oxygenate the incubation mixture, and to include sufficient buffering capacity to prevent acidification due to gluconic acid formation during the procedure. Under these conditions, an initial concentration of 200 mmol/l of urinary glucose could be reduced to an acceptable 55 f 23 pmol/l (mean f SD, n = 5 ) within 3 h with good recovery of the probe sugars (L-arabinose 93.2 f 1.5%, lactose 86.6 & 1.7%, raffinose 88.7 It 1.0%).
Validation of assays
Although the individual methods are all well established in other contexts, each enzymatic procedure was optimized for the microfluorimetric determination of probe sugars in urine. Incubation conditions were adjusted so that each reaction was essentially complete within 30 min and each sugar produced at least 90% of the stoichiometric equivalent of NAD( P)H. For each procedure there was a linear relationship between relative fluorescence and sugar concentration extending over two orders of magnitude (Table 2 ) and deviating from linearity at final NAD(P)H concentrations greater than approximately 30 pmol/l. Reproducibility of each method was better than 5% at half-maximum concentration (Table 2) , falling to between 5% and 9% at concentrations below 5% of maximum.
The specificity of each procedure was investigated by measuring the detectability of, and interference from, each sugar in the assay for another using 'worst-case' combinations of sugars formulated from the data obtained in the patient study. At the concentrations tested (see Table 3 ), only L-arabinose was detectable in the assays for lactose and raffiiose (at an apparent concentration of 1.5 and 1.8 Table 1 . Comparison of ion-exchange and solid-phase extraction for the removal of endogenous urinary fluorescence The fluorescence of pooled urine containing known amounts of each sugar probe was measured before and after extraction with AG501-X8 mixed ion-exchange resin or with BondElut C18 columns as described in the text. Sugar recovery was determined after extraction. Results are means f SD. pmol/l, respectively) and no extraneous sugar was detected in the L-arabinose assay; the amounts of endogenous fructose and galactose in urine specimens were insufficient to interfere in the raffinose or L-arabinose determinations. As shown in Table 3 , limited cross-interference between sugars was observed in these worst-case experiments, but such sugar combinations were rarely encountered in practice and in no case would allowing for their effect have altered the outcome of the test.
Reduction in
Metabolism of sugars
The metabolic stability only of L-arabinose was investigated, since published data concerning that of raffhose and lactose is already available [22] . After intravenous injection of a sterile, pyrogen-free solution containing 500 mg of L-arabinose in 5 ml of water in five normal volunteers, 63.3 f 4.1% (mean f SD) was excreted in the urine within 5 h and 73.1 k 4.5% within 12 h.
Excretion of ingested sugars in normal subjects
The median concentration of probe sugar excreted in the 5 h urine in the normal volunteers was 8.92 mmol/l (range 2.41-26.51 mmol/l) for L-arabinose, 110.9 pmol/l (32.1-703.4 pmol/l) for raffinose and 85.9 pmol/l (22.6-587.0 ,umol/l) for lactose, all well within the linear Table 2 . Performance characteristics for fluorimetric determination of probe sugars in urine Sugars were dissolved in pooled urine to give a broad range of final concentration and each solution was analysed in triplicate. Sensitivity is expressed as a concentration equivalent to the blank fluorescence + 3 SDS ( n = 5), linearity as the upper limit of the linear range, and precision as the coefficient of variation for a half-maximal sugar concentration ( n = 10). range of the appropriate assay. The corresponding percentage recoveries (Table 4) indicate that absorption of Larabinose was at least 68-fold greater than that of raffinose, which in turn was over five times that of intact lactose. However, there was considerable variation in both concentration and recovery between subjects, with an approximately tenfold range for each sugar. For raffinose, the spread of the data was not altered when excretion was expressed as a ratio relative to L-arabinose (Fig. l) , although there was some improvement for lactose ( Fig. 2 and Table 4 ).
Sugar excretion in patients with gastrointestinal disease
Coeliac disease. In patients with untreated coeliac disease there was a highly significant reduction in Larabinose recovery and an increase in both raffinose and lactose recoveries (Table 4) . There was thus a highly significant increase in both the raffinose/L-arabinose and lactose/L-arabinose excretion ratios. However, whereas the recovery data for individual sugars, especially r a i nose, overlapped with the normal results, there was a complete separation from the normal group for both ratios ( Figs. 1 and 2 ). In patients in partial remission all parameters remained sigmficantly different from normal, although much less so than in untreated patients and with considerable overlap with the corresponding normal data. In fully recovered patients, L-arabinose recovery remained significantly depressed, although raffinose and lactose recoveries had returned to normal (Table 4) , and both excretion ratios were thus significantly greater than, but overlapping with, normal (Figs. 1 and 2 ).
Lactase deficiency. In patients with proven lactase deficiency, not only was urinary lactose recovery significantly elevated but L-arabinose recovery was significantly lower than, although overlapping with, normal (Table 4) . Because of this both excretion ratios were significantly raised. However, the raffinose/L-arabinose excretion ratios all lay within the range of the normal group (Fig. 1 , whereas the lactose/L-arabinose excretion ratios were completely separated from those of the normal group (Fig. 2) .
Inflammatory bowel disease. There was a clear difference between patients with ulcerative colitis and those with Crohn's disease, the former having a decreased lactose recovery as the only significant difference from normal. In Crohn's patients as a whole, L-arabinose recovery was slightly but sigmficantly less than normal and raffinose recovery was substantially increased, giving a significantly raised raffiinose/L-arabinose excretion ratio. However, neither lactose recovery nor the lactose/Larabinose excretion ratio was affected. When the results in Crohn's disease were analysed according to site, it was clear that only patients with extensive small-bowel involvement showed any change from normal, having increased raffimose and lactose recoveries and excretion ratios, whereas patients with disease confined to the terminal ileum and large intestine had entirely normal probe excretion ( Figs. 1 and 2 ). IBS. Patients with IBS showed minimal alteration in sugar probe excretion, with a small decrease in Larabinose recovery (Table 4 ) and a slight increase in the lactose/L-arabinose excretion ratio (Fig. 2) as the only significant changes.
DISCUSSION
Differential sugar absorption tests depend on the use of two or more sugars which differ only in respect of their intestinal absorption, so that a ratio of the amounts excreted in the urine provides an index of a particular intestinal function [22, 231. In this way the influence of extraneous factors, such as gastric emptying, intestinal transit and renal function, can be largely eliminated. The probe sugars should be essentially exogenous, excreted in the urine quantitatively and unchanged after absorption and, in the context of permeability assessment, they should also be absorbed only by unmediated permeation and be resistant to intestinal metabolism [23, 24] . The trisaccharide raffinose (Galpa 1-6Glcpa l-2Frufi and the monosaccharide L-arabinose satisfy these essential requirements and are easily measured enzymatically. They are plant sugars and thus components of a normal diet [25, 261, but Intestinal permeation of hydrophilic molecules of radius 0.4 nm or less, e.g. L-arabinose (mol. wt. 150, radius approx. 0.3 nm), is believed to occur predominantly by free diffusion through numerous small aqueous pores, probably located in the enterocyte luminal surface membrane [23, [29] [30] [31] [32] [33] . Larger molecules, such as raffimose (mol. wt. 504, radius 0.59 nm), appear to be excluded from this transcellular pathway and penetrate the mucosa more slowly through larger, less numerous channels which are believed to be paracellular in location [23, [33] [34] [35] [36] [37] . Expressing the urinary recovery of the probes as a ratio relative to L-arabinose corrects not only for extraneous factors such as transit, but also for changes in intestinal surface area [23, 24, 271 . The raffinose/Larabinose excretion ratio thus constitutes an index of paracellular permeability to raffinose in vivo, as demon-
Coeliac disease
Crohn's disease Fig. 2 . Lactose/L-arabinose excretion ratios in normal subjects and patients with gastrointestinal disease, expressed as a ratio of the percentage of the ingested dose of each sugar recovered in a 5 h urine collection. The median for each group is marked with an arrow, and the upper limit of normal is denoted by the broken horizontal line. S i m c a n c e values (Mann-Whitney U-test) for each patient group compared with the normal group are shown in parentheses.
in Crohn's disease patients are in broad agreement with some studies, where an abnormal sugar excretion ratio [2-51 or 5*Cr-ethylenediaminetetra-acetate permeation [7] was associated with small-bowel involvement, but not others, where abnormal permeability to sugars [40] or poly(ethy1ene glycol) [9] was found in patients with Crohn's disease apparently confined to the colon. This discrepancy may be partly attributed to differing test protocols and diagnostic criteria, but much may be due to inter-patient variation and the small size of the groups studied. In their more extensive study, Andre et al. [42] concluded that the prevalence of abnormal sugar permeabilty in Crohn's disease was too low to be clinically useful except in patients in relapse. It has long been known that lactosuria is associated with impaired lactose digestion [46, 47] . Menzies and COworkers [22, 431 convincingly demonstrated that, when expressed as a ratio relative to a non-hydrolysable disaccharide such as lactulose, the urinary excretion of ingested lactose provided a good index of lactose intolerance. We found that, despite the excellent theoretical arguments [22, 43] in favour of a lactose/oligosaccharide excretion ratio, diagnostic sensitivity is much improved by making use of the lactose/monosaccharide excretion ratio. Thus lactose/raffinose excretion ratios in patients with proven lactase deficiency (median 0.73, range 0.37-1.07) were substantially greater than normal (0.2, 0.07-0.75, P < 0.0001 ), but with appreciable overlap between the groups. Furthermore, the lactose/raffinose excretion ratio in untreated coeliac disease was essentially normal (0.26, 0.08-0.59, P = 0.058). The lactose/L-arabinose excretion ratio, however, not only detected lactose maldigestion in all the patients with lactase deficiency, but also clearly indicated its presence in 93% of the untreated coeliac group. It can be shown from the data of Noone et al. [43] that the expression of lactosuria as a lactose/rhamnose excretion ratio would have improved the discrimination of their combined procedure in patients with rotaviral gastroenteritis (range 0.33-1.00 in infection versus 0.13-0.4 1 in control subjects for the lactose/lactulose excretion ratio, compared with 0.033-0.59 versus 0.001 5-0.01 1 for the lactose/rhamnose excretion ratio). The reason for this improvement is unclear, but lactose hydrolysis is a mucosal surface phenomenon and expressing lactose recovery relative to monosaccharide provides a correction for mucosal surface area [27] , so that the excretion ratio may reflect inversely a 'specific activity' for lactose hydrolysis relative t o mucosal surface.
Whatever the reason, the improvement in diagnostic sensitivity is considerable and enables the lactose intolerance of untreated coeliac disease [47, 
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